目的：评估苏茵解毒方对中晚期慢性肾脏病（CKD）肾虚浊毒证患者的疗效及对中医证候转归的影响。方法：回顾性纳入2023年5月至2025年5月在我院接受诊治的120例中晚期CKD患者，按所接受治疗不同分为对照组与观察组，每组各60例。两组患者均给予现代医学综合治疗作为基础治疗，包括原发病及并发症控制、血压血糖管理、肾脏保护及相关并发症的规范化处理，疗程3个月；观察组患者在此基础上加用苏茵解毒方治疗。比较两组患者的临床疗效，治疗前及治疗3个月后的中医证候积分指标、肾功能指标［尿素氮（BUN）、血肌酐（Scr）、估算肾小球滤过率（eGFR）、24 h尿蛋白定量（24 h UTP）］、炎症反应指标［C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）］以及不良反应发生情况；并采用相关分析与多元线性回归分析探讨中医证候总积分与肾功能指标之间的关系。结果：观察组患者治疗总有效率为93.33%，高于对照组的80.00%（P<0.05）。治疗3个月后，两组患者中医证候积分、BUN、Scr、24 h UTP及炎症指标较治疗前均降低（P<0.05），eGFR较治疗前均升高（P<0.05），且观察组患者以上指标改善幅度高于对照组患者（P<0.05）。相关性分析显示，治疗3个月后，患者中医证候总积分与Scr、BUN、24 h UTP呈正相关（r=0.46~0.58，P<0.001），与eGFR呈负相关（r=-0.52，P<0.001）；多元线性回归分析提示，中医证候总积分是Scr和eGFR变化的独立相关因素（P<0.05）。两组患者不良反应发生率比较，差异无统计学意义（观察组13.33%，对照组8.33%，P>0.05）。结论：在现代医学综合治疗基础上联合应用苏茵解毒方，可改善中晚期CKD肾虚浊毒证患者的中医证候及肾功能，并减轻系统性炎症反应；中医证候改善程度与肾功能变化密切相关，提示其具有一定的“证-指标”一致性，且治疗总体安全性良好。

Objective： To evaluate the clinical efficacy of Suyin jiedu formula in patients with moderate to advanced chronic kidney disease （CKD） with the syndrome of kidney deficiency and turbid toxin， and to investigate its influence on the prognosis of traditional Chinese medicine （TCM） syndromes.Methods： A total of 120 patients with moderate to advanced CKD treated in our hospital between May 2023 and May 2025 were retrospectively enrolled and divided into the control group and the observation group according to the treatment received， with 60 cases in each group. Both groups received standard comprehensive treatment， including management of primary disease and complications， blood pressure and glucose control， renal protection， and standardized treatment of CKD-related complications， for 3 months. The observation group additionally received suyin jiedu formula treatment. The clinical efficacy， TCM syndrome scores ， renal function indicators ［blood urea nitrogen （BUN）， serum creatinine （Scr）， estimated glomerular filtration rate （eGFR）， and 24 h urinary total protein （24 h UTP）］， inflammatory markers ［C-reactive protein （CRP）， tumor necrosis factor-α （TNF-α）， and interleukin-6 （IL-6）］ before and after 3 months of treatment， and incidence of adverse reactions were compared between the two groups. Correlation analysis and multivariate linear regression analysis were performed to explore the relationship between total TCM syndrome scores and renal function indicators.Results： The total effective rate in the observation group （93.33%） was higher than that in the control group （80.00%） （P < 0.05）. After 3 months of treatment， the TCM syndrome scores， BUN， Scr， 24 h UTP， and inflammatory markers of the two groups of patients decreased， while eGFR increased， with more pronounced improvements observed in the observation group （P < 0.05）. Correlation analysis showed that the total TCM syndrome score was positively correlated with Scr， BUN， and 24 h UTP （r = 0.46–0.58， P < 0.001）， and negatively correlated with eGFR （r = -0.52， P < 0.001）. Multivariate linear regression analysis indicated that the total TCM syndrome score was an independent related factor for the changes of Scr and eGFR （P < 0.05）. There was no statistical difference in the incidence of adverse reactions between the two groups （13.33% vs. 8.33%， P > 0.05）.Conclusion： On the basis of modern comprehensive medical treatment， the addition of suyin jiedu formula can significantly improve TCM syndromes， renal function， and alleviate systemic inflammatory responses in patients with moderate to advanced CKD with kidney deficiency and turbid toxin syndrome. The degree of improvement of TCM syndromes is closely associated with changes in renal function， suggesting a certain degree of consistency between TCM syndrome evolution and clinical parameters， and the overall safety of this treatment is good.